Figure - available from: Cancer Chemotherapy and Pharmacology
This content is subject to copyright. Terms and conditions apply.
PFS and OS comparison between combination and single-agent treatment in TFI ≥ 6 months advanced NSCLC patients. a The PFS in the combination and single-agent treatment groups. b The OS in the combination and single-agent treatment groups
Source publication
Purpose
Doublet combination chemotherapy is commonly considered a second-line treatment for advanced non-small cell lung cancer (NSCLC) in China. This multi-institutional retrospective analysis evaluated and compared the efficacy between combination and mono-therapy after platinum-based first-line chemotherapy in Chinese patients with advanced NSCL...
Similar publications
Anti-PD1 and anti-PD-L1 agents may have intrinsic and clinically relevant differences in the treatment of non-small cell lung cancer (NSCLC) patients. By reviewing currently available indirect evidence on these agents for NSCLC treatment, highlighting possible inter- and intra-class dissimilarities, anti-PD1 agents showed a higher response rate and...
Simple Summary
Extended small cell lung cancer (ED-SCLC) remains an aggressive disease without major advances in the last 20 years. Recently, new therapies have eventually improved the outcomes of these patients, completely overturning their management. The objective of this review is to describe the most recent advances in ED-SCLC treatment, start...
Background
The association between obesity and outcomes in patients receiving programmed death-1/programmed death ligand-1 (PD-L1) checkpoint inhibitors has already been confirmed in pre-treated non-small cell lung cancer (NSCLC) patients, regardless of PD-L1 tumor expression.
Methods
We present the outcomes analysis according to baseline body mas...
Purpose: Patients with lung cancer and interstitial lung disease treated with radiotherapy have been reported to be at a risk of developing radiation pneumonitis. However, the association between interstitial lung abnormalities (ILA) and radiation pneumonitis in patients with limited-stage small cell lung cancer (LS-SCLC) remains unclear. Furthermo...
Citations
... However, most studies did not distinguish or categorize the patients by factors that might impact the potential benefit from the second-line combination chemotherapy. By c ontrast, platinum-base d doublet chemotherapy was revealed to be the preferred second-line option over single-agent chemotherapy in clinical practice from two Chinese retrospective studies and conferred improved OS especially in patients with longer treatment-free interval (TFI) or time to progression from first-line chemotherapy (15,16). ...
... The patients with a TFST of > 9 months had a much longer PFS (8.7 months) than those with a TFST of ≤ 9 months (5.0 months). In other words, TFST from firstline chemotherapy could distinguish the patients who might benefit the most from second-line therapy, which was confirmed in two previous Chinese retrospective studies (15,16). Both a TFST of > 12 months and a TFI of > 6 months from first-line chemotherapy were independent predictive factors of favorable PFS and OS in advanced NSCLC patients who received platinum-based doublet chemotherapy in the second-line setting. ...
... Indeed, in the NJLCG0804 trial (32), among NSCLC patients whose treatment with epidermal growth factor receptor tyrosine kinase inhibitors and platinumbased chemotherapy failed, S-1 and irinotecan combination therapy demonstrated high effectiveness; the ORR reached 52.0%, and PFS and OS were 5.0 and 17.1 months, respectively. Third, although we did not find a significant difference in survival benefit among patients from different centers, it should be noted that most patients in this study were from the sponsor's cancer center, while platinum-based doublet chemotherapy as second-line option seemed to be more popular in other institutions from the same province (15). ...
Background
For patients who have contraindications to or have failed checkpoint inhibitors, chemotherapy remains the standard second-line option to treat non-oncogene-addicted advanced non-small cell lung cancer (NSCLC). This study aimed to investigate the efficacy and safety of S-1-based non-platinum combination in advanced NSCLC patients who had failed platinum doublet chemotherapy.
Methods
During January 2015 and May 2020, advanced NSCLC patients who received S-1 plus docetaxel or gemcitabine after the failure of platinum-based chemotherapy were consecutively retrieved from eight cancer centers. The primary endpoint was progression-free survival (PFS). The secondary endpoint was overall response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. By using the method of matching-adjusted indirect comparison, the individual PFS and OS of included patients were adjusted by weight matching and then compared with those of the docetaxel arm in a balanced trial population (East Asia S-1 Trial in Lung Cancer).
Results
A total of 87 patients met the inclusion criteria. The ORR was 22.89% (vs. 10% of historical control, p < 0.001) and the DCR was 80.72%. The median PFS and OS were 5.23 months (95% CI: 3.91–6.55 months) and 14.40 months (95% CI: 13.21–15.59 months), respectively. After matching with a balanced population in the docetaxel arm from the East Asia S-1 Trial in Lung Cancer, the weighted median PFS and OS were 7.90 months (vs. 2.89 months) and 19.37 months (vs. 12.52 months), respectively. Time to start of first subsequent therapy (TSFT) from first-line chemotherapy (TSFT > 9 months vs. TSFT ≤ 9 months) was an independent predictive factor of second-line PFS (8.7 months vs. 5.0 months, HR = 0.461, p = 0.049). The median OS in patients who achieved response was 23.5 months (95% CI: 11.8–31.6 months), which was significantly longer than those with stable disease (14.9 months, 95% CI: 12.9–19.4 months, p < 0.001) or progression (4.9 months, 95% CI: 3.2–9.5 months, p < 0.001). The most common adverse events were anemia (60.92%), nausea (55.17%), and leukocytopenia (33.33%).
Conclusions
S-1-based non-platinum combination had promising efficacy and safety in advanced NSCLC patients who had failed platinum doublet chemotherapy, suggesting that it could be a favorable second-line treatment option.
... (23). After first-line therapy, the patient still had a good performance status and was eligible for further platinum combination chemotherapy (24). To minimise adverse effects, the dosage of lobaplatin was lowered. ...
Immune-related adverse events following treatment with immune checkpoint inhibitors (ICIs) can occur at any time during therapy, with onset occurring most frequently during the first 3 months of treatment. However, they rarely occur after treatment cessation. An awareness of delayed immune-related events following the termination of immunotherapy is paramount for optimal tumour management. The present study reports a case of a 69-year-old male patient with right lung adenocarcinoma. He suffered from psoriasis for ~40 years and was suspected of developing immune checkpoint inhibitor-related pneumonitis (CIP) 6 months after the cessation of treatment with the anti-programmed cell death-1 receptor antibody sintilimab. The present case study is, to the best of our knowledge, the first case of late-onset CIP after the cessation of sintilimab. Subsequently, the report also reviews previously reported cases of late-onset CIP after the cessation of ICI treatment. The present report highlights the finding that CIP can develop, although rarely reported, months or even years after the termination of immunotherapy. Therefore, CIP should always be considered as one of the possibilities and addressed accordingly once the pulmonary infection is ruled out. Careful monitoring, timely diagnosis and administration of corticosteroids are essential in controlling this condition, particularly for patients with pre-existing autoimmune diseases.
... 19 Compared with second-line docetaxel chemotherapy, treatment with nivolumab or pembrolizumab provided a better ORR and OS. [20][21][22] The combination of anlotinib hydrochloride and Immune checkpoint inhibitors is effective and well-tolerated in patients with NSCLC. 23 Therefore, we assessed the efficacy and safety of anlotinib combined with immune checkpoint inhibitors as salvage treatment in patients with progress of local advance NSCLC in half a year after standard treatment and investigated the predictors of therapeutic efficacy. ...
... Our results showed that the combination of anlotinib and immunotherapy had good efficacy, with median PFS and OS reaching 10 and 14 months respectively, which is significantly higher than that reported in the previous literature for second line chemotherapy. 21,34 Regarding toxicity in study, the overall incidence of treatment-related AEs was 66.7%, The most common AEs during treatment were hypertension(36.8%),which is higher than that of previous reported. ...
Purpose:
As for local advanced non-small cell lung cancer (NSCLC), synchronous radiotherapy and chemotherapy is the standard treatment mode. But for patients with progress in half a year, which means the second-line chemotherapy effect is not ideal for them. We observed the efficacy and safety of anlotinib hydrochloride combined with PD-1 blockade as the second-line treatment for those patients in this trial.
Patients and methods:
From January 2018 to December 2019, 57 patients with the progress of local advanced NSCLC treated with anlotinib plus PD-1 blockade until disease progression or intolerance as a result of adverse events. Patients have been assessed using computed tomography prior to treatment and during follow-up every 2 months until disease progression or death. The primary endpoint was objective response rate (ORR). The secondary endpoints included overall survival (OS), progression-free survival (PFS) and safety. Survival curves were created using the Kaplan-Meier method.
Results:
57 patients were enrolled. The median age was 64 years, and 61.4% of the patients were men. The ORR was 50.9% with a median OS time of 14 months and the 1-year OS rates and PFS rates were 81.8% and 33.3%, respectively. The patients with squamous cell carcinoma, no brain or liver metastases had longer PFS than patients with liver metastasis. When the PFS was calculated from the time of second treatment, the median PFS was 9 months. Most adverse events (AEs) were grade 1-3, one drug-related death was noted.
Conclusion:
The expected outcome of this study is that anlotinib combined with PD-1 blockade has tolerable toxicity and better ORR, OS than second-line chemotherapy. The results may indicate additional treatment options for patients with progress of local advance NSCLC in half a year after standard treatment.
... Cancer is a complex disease driven by multiple gene mutations, and its progression involves interaction between cancer cells and their microenvironment [213]. Compared to single-agent therapy, combination chemotherapy has shown better clinical treatment effects, especially in delaying the development of cancer chemotherapy resistance [214,215]. Studies have found that cancer cells acquire defense mechanisms by over-expressing drug efflux pumps, increasing drug metabolism, enhancing self-repair capabilities, or expressing altered drug targets, resulting in reduced efficacy and, ultimately, failure of treatment [61]. In order to solve this problem, the use of two or more drugs with different pharmacological mechanisms for combined therapy is a promising treatment strategy (Table 4). ...
Cancer is one of the primary causes of worldwide human deaths. Most cancer patients receive chemotherapy and radiotherapy, but these treatments are usually only partially efficacious and lead to a variety of serious side effects. Therefore, it is necessary to develop new therapeutic strategies. The emergence of nanotechnology has had a profound impact on general clinical treatment. The application of nanotechnology has facilitated the development of nano-drug delivery systems (NDDSs) that are highly tumor selective and allow for the slow release of active anticancer drugs. In recent years, vehicles such as liposomes, dendrimers and polymer nanomaterials have been considered promising carriers for tumor-specific drug delivery, reducing toxicity and improving biocompatibility. Among them, polymer nanoparticles (NPs) are one of the most innovative methods of non-invasive drug delivery. Here, we review the application of polymer NPs in drug delivery, gene therapy, and early diagnostics for cancer therapy.
